Cellectis has raised $ 164 m from a US public offering to expand its CAR - T and gene - editing capabilities . The SEC filing noted that Allogene has assumed all of Pfizer’s obligations—which could generate up to $2.8 billion for Cellectis—and has also taken over U.S. rights to lead CAR-T UCART19 for acute lymphoblastic leukemia, which is licensed to Server elsewhere. The French company is planning to spend $ 100 m of the funding on further commercial production , including setting up a manufacturing facility for its CAR - T candidates , $ 20 m on further clinical development on another programme and $ 30 m to develop its gene - editing technology for non - oncological uses . Meanwhile , Cellectis ’s partnership with Pfizer for 17 readymade AR - Ts has been converted into a new company , Allogene , which has taken over the rights to lead CAR - T UCART19 for acute lymphoblastic leukaemia , and is backed by $ 300 m of funding .
Cellectis has raised $ 164 m from a US public offering to expand its CAR - T and gene - editing capabilities . The French company is planning to spend $ 100 m of the funding on further commercial production , including setting up a manufacturing facility for its CAR - T candidates , $ 20 m on further clinical development on another programme and $ 30 m to develop its gene - editing technology for non - oncological uses . Meanwhile , Cellectis ’s partnership with Pfizer for 17 readymade AR - Ts has been converted into a new company , Allogene , which has taken over the rights to lead CAR - T UCART19 for acute lymphoblastic leukaemia , and is backed by $ 300 m of funding .